CardioFocus的封面图片
CardioFocus

CardioFocus

医疗设备制造业

Lesion Creation at the Speed of Light

关于我们

CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AFib), the most common heart arrhythmia. The company’s FDA-approved HeartLight Endoscopic Ablation System has successfully treated more than 10,000 patients in the United States, Europe and Japan. The HeartLight System is a revolutionary catheter ablation technology that along with direct visualization and titratable laser energy, represents a new standard for AFib ablation. CardioFocus is headquartered in Marlborough, MA. For more information, visit www.CardioFocus.com. Social Media Community Guidelines: bit.ly/2IDIBZR

网站
https://cardiofocus.com
所属行业
医疗设备制造业
规模
51-200 人
类型
私人持股
领域
Atrial fibrillation

地点

CardioFocus员工

动态

  • 查看CardioFocus的组织主页

    8,201 位关注者

    We're excited to share that our OptiShot? PFA Balloon Catheter — a next-generation, ultra-compliant balloon for PVI — has been selected for the PFA Live Case Summit 2025, happening just before HRS in San Diego! A first-in-human OptiShot case will be presented by Dr. Vivek Reddy, highlighting how this balloon combines direct visualization and advanced PFA science for precise and consistent PVI. ??? When: Thursday, April 24 ?? Where: San Diego Convention Center, Room 20A #EPeeps attending the summit — don't miss the chance to see OptiShot in action! Note: The OptiShot PFA Balloon System is investigational and not approved for commercial use.

    • 该图片无替代文字
  • 查看CardioFocus的组织主页

    8,201 位关注者

    #BigNews: CardioFocus is proud to announce a strategic partnership with Japan Lifeline (JLL) to bring our Pulsed Field Ablation (PFA) technology to more physicians and patients worldwide! Through this collaboration, JLL will help develop and manufacture our QuickShot PFA catheter, while CardioFocus will continue to advance our PFA generator. JLL will also lead commercialization in Japan, South Korea, and Taiwan, while we focus on the US and Europe. This partnership strengthens our commitment to delivering next-generation PFA solutions that improve outcomes for patients with atrial fibrillation. We’re thrilled to join forces with JLL to accelerate innovation in electrophysiology! Read the full announcement here: https://ow.ly/bNCp50V8no7 #PFA #Epeeps #AFib Note: QuickShot is not currently approved for commercial use in any geography.

    • 该图片无替代文字
  • 查看CardioFocus的组织主页

    8,201 位关注者

    Watch Centauri Focal PFA in action! Dr. Atul Verma at Southlake Regional Health Centre in Ontario performs a focal PFA ablation using the Centauri System—demonstrating how this technology gives physicians the flexibility to customize their ablation strategy for each patient. Watch here: https://ow.ly/jKuz50UZuA7 #PFA #epeeps #PFACentauri #X3Vision Note: Centauri is not for sale in the US.

  • 查看CardioFocus的组织主页

    8,201 位关注者

    Have you ever seen the pulmonary veins through a camera during ablation? In this case presentation from #AFSymposium2025, Dr. Vivek Reddy demonstrates how the OptiShot PFA Balloon’s endoscopic visualization offers direct feedback on balloon stability and contact—critical factors to ensure a successful PVI. This approach highlights the importance of visual feedback in advancing safe and effective PFA procedures. Watch the clip to see it in action. #PFA #OptiShotPFA #Epeeps #AFib Note: OptiShot is not currently approved for commercial use in any geography.

  • 查看CardioFocus的组织主页

    8,201 位关注者

    Last week at #AFSymposium2025, our Centauri focal PFA received recognition in several presentations, our OptiShot PFA Balloon was in the spotlight, and we showcased our commitment to a portfolio approach to #PFA that addresses diverse clinical needs. Thank you to everyone who engaged with us—this is just the beginning of what’s to come.. ?? Couldn't join us in Boston? Swipe through to relive some highlights from the event ?? Note: The Centauri system is not approved for sale in the United States. QuickShot and OptiShot are not currently approved for commercial use in any geography.

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
  • 查看CardioFocus的组织主页

    8,201 位关注者

    What an incredible moment at #AFSymposium2025! A huge thank you to Dr. Vivek Reddy for unveiling one of the VISION-AF first-in-human OptiShot PFA Balloon cases from Prague. This case highlighted the power of direct endoscopic visualization of contact, ultra-compliant balloon stability during PFA delivery under deep sedation, and the seamless integration of advanced balloon technology with optimized PFA waveforms—a huge leap forward in #AFib ablation! We also want to express our gratitude to Professor Petr Neuzil, Dr. Jan Petr?, Dr. Moritoshi Funasako, and Dr. Jan ?koda for their invaluable contributions to making this a success. We’re proud to collaborate with such inspiring leaders in the field and honored to share this pivotal moment with the #epeeps community as we continue to push the boundaries of innovation together. Note: OptiShot is not currently approved for commercial use in any geography.

    • 该图片无替代文字
    • 该图片无替代文字
  • 查看CardioFocus的组织主页

    8,201 位关注者

    Step behind the scenes tomorrow at the #AFSymposium2025! Our tech suite offers a closer look at the most innovative developments in #PFA for the treatment of atrial fibrillation! ?? Find us in MR3 on the exhibit floor Appointments are limited - comment below or DM us to secure a spot today. #epeeps Note: The Centauri system is not approved for sale in the United States. QuickShot and OptiShot are not currently approved for commercial use in any geography.

  • 查看CardioFocus的组织主页

    8,201 位关注者

    #JustPublished: We are thrilled to announce the publication of the ECLIPSE AF 1-year clinical trial results in Circulation: Arrhythmia & Electrophysiology! Key findings: ? 90.2% freedom from clinically significant atrial arrhythmia in paroxysmal AF patients undergoing point-by-point PVI with the Centauri System and WAVE1 monopolar PFA waveform ? 89% chronic PVI durability rate in optimized cohorts ? Safe and effective workflows with commercial contact force focal catheters These results highlight the potential of our CE-marked Centauri PFA technology, which has already treated over 6,000 patients, to transform #AFib ablation by delivering strong efficacy and a robust safety profile. This marks another step forward as we advance the science of #PFA with innovative solutions like the investigational QuickShot Nav Catheter and the OptiShot PFA Balloon Catheter. Thank you to our investigators and authors for their contributions to this clinical trial: Ante Anic, MD, Thomas Phlips, MD, Toni Breskovic, MD, Vik M., Steven Girouard, PhD, Zrinka Juri?i?, MD, Ivan Sikiric, MD , Lucija Lisica Kordi?, MD, Pieter Koopman, MD, Nathalie Antole, MD, and Johan Vijgen, MD. Read our press release: https://ow.ly/AvGI50UGx0K Link to the full study: https://ow.ly/P2L450UGx0J www.cardiofocus.com #PFA #Centauri #epeeps #AFIB Note: Centauri is not approved for sale in the United States.

    • 该图片无替代文字

相似主页

查看职位

融资

CardioFocus 共 20 轮

上一轮

未知

US$27,155,857.00

Crunchbase 上查看更多信息